Apokyn (apomorphine hydrochloride injection) is used to treat acute hypomobility ‘off’ episodes linked to advanced Parkinson’s disease.
Following the move, Ipsen will not record Apokyn sales in its accounts from 30 November 2011
Britannia on the other hand will take charge of continuity of supply and support of Apokyn through USWorldMeds, which will commercialise Apokyn in the US.